Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00990236 · ClinicalTrials.gov registry record · NA
Thrombelastography Based Dosing of Enoxaparin
A NA study of Thromboembolic Complications, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- NA
- Development phase
- 185
- Enrollment target
- 3
- Study locations
NCT00990236: Completed NA study of Thromboembolic Complications, sponsored by Oregon Health and Science University.
NCT00990236 is a NA study of Thromboembolic Complications that has completed, run by Oregon Health and Science University. The registered enrollment target is 185 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (87% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00990236, a NA study of Thromboembolic Complications, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- NA
- Development phase
- 185 participants
- Enrollment target
- 3
- Study locations
Study Summary
The risk of developing a blood clot occurs in up to 60% of all critical care patients. Many times enoxaparin (or Lovenox®) is given to patients who are at a higher risk of developing clots in their legs or lungs. Recent data suggest that a standard dose of Lovenox may not fully prevent the development of these clots especially in critically ill or obese patients. Routine enoxaparin dosing can also result in bleeding complications. Thrombelastography (TEG®) can be used to measure how blood clots. The purposes of this study are: * to learn if the TEG® can better guide physicians in prescribing an effective dose of Lovenox compared to standard doses recommended by the drug company in preventing blood clots from developing in the legs and lungs, and * to compare the development of blood clots in patients receiving the standard dose of enoxaparin compared to patients receiving a TEG® guided dose of enoxaparin. * to determine if TEG guided dosing results in decreased bleeding complications compared to standard dosing.
Primary Outcome
An ultrasound duplex will be completed at least one time after randomization to determine if the subject has developed a DVT.
Conditions Studied
Interventions
- DRUG Enoxaparin dose adjusted Lovenox based on TEG
- DRUG Enoxaparin 30 mg BID
Study Locations (3)
Oregon
- Oregon Health & Science University - Portland
Texas
- University of Texas Health Science Center at Houston - Houston
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 185 participants |
| Start Date | 2009-09 |
| Est. Completion | 2015-03 |
| Phase | NA |
What the finished NCT00990236 record still lists
NCT00990236 is an interventional study that assigns participants to a tested intervention. The registered 185 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Thromboembolic Complications appearing as the primary indexed condition, and to 2 interventions - of which Enoxaparin dose adjusted Lovenox based on TEG is the first listed.
NCT00990236 reports a single indexed study location in Oregon, Texas, Washington.
Frequently Asked Questions
What is clinical trial NCT00990236 about?
NCT00990236 is a clinical study titled "Thrombelastography Based Dosing of Enoxaparin". The risk of developing a blood clot occurs in up to 60% of all critical care patients. Many times enoxaparin (or Lovenox®) is given to patients who are at a higher risk of developing clots in their legs or lungs. Recent data suggest that a standard dose of Lovenox may not fully prevent the developme...
What is the current status of trial NCT00990236?
This trial is currently completed. It is a NA study. The enrollment target is 185 participants. The study started on 2009-09. Estimated completion is 2015-03.
What conditions does trial NCT00990236 study?
This clinical trial studies the following conditions: Thromboembolic Complications.
What interventions are being tested in trial NCT00990236?
The interventions under investigation include: Enoxaparin dose adjusted Lovenox based on TEG (DRUG), Enoxaparin 30 mg BID (DRUG).
Who is sponsoring clinical trial NCT00990236?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00990236 being conducted?
This trial has 3 study locations across Oregon, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00990236's enrollment target sits among peer trials
185 580th of 2000 higher than 1,420 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04041154 · 185 participants · NA
Behavioral and Neural Representations of Subjective Effort Cost
- NCT04484272 · 185 participants · NA
A Stress and Pain Self-management m-Health App for Adult Outpatients With Sickle Cell Disease
- NCT05020860 · 185 participants · Phase 2
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
- NCT05793541 · 185 participants · NA
Just-in-time Interventions for Reducing Short-term Suicide Risk
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia